Themis Medicare's Q1 FY 2025-26 Quarter Results

Result Summary

• Themis Medicare Ltd reported a 0.2% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Jun (Q1 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 20.3%.
• Its expenses for the quarter were up by 20.2% QoQ and 14.3% YoY.
• The net profit decreased 314.2% QoQ and decreased 157.6% YoY.
• The earnings per share (EPS) of Themis Medicare Ltd declined at 1.5 during Q1 FY 2025-26.

Financial Statments for Q1 FY 2025-26

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Themis Medicare Ltd is a pharmaceutical company that operates in the healthcare industry, focusing on the development, manufacture, and commercialization of pharmaceutical products. The company specializes in the manufacture of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. Over the years, Themis Medicare has built a robust portfolio of products catering to various therapeutic areas, including anti-tuberculosis, anti-malarial, pain management, and cardiovascular segments. As of the latest updates, there are no specific major developments available in the data provided.

Revenue

For Q1FY26, Themis Medicare Ltd reported a total income of ₹98.75 crores, a slight decrease of 0.2% compared to the previous quarter (Q4FY25), where the total income was ₹98.92 crores. When compared year-over-year (YoY), there is a significant decrease of 20.3% in total income from Q1FY25, which reported ₹123.95 crores. This reduction in revenue over the year reflects a notable shift in the company's income generation for this quarter.

Profitability

The company's profitability metrics for Q1FY26 indicate a challenging quarter with a reported loss before tax of ₹13.93 crores, contrasting sharply with a profit before tax of ₹5.18 crores in Q4FY25 and ₹25.37 crores in Q1FY25. The quarter-over-quarter (QoQ) change is a substantial decline of 368.9%, and the year-over-year (YoY) change is a decrease of 154.9%. Consequently, the profit after tax for Q1FY26 is recorded at a loss of ₹14.22 crores, compared to a profit of ₹6.64 crores in Q4FY25 and ₹24.68 crores in Q1FY25, representing declines of 314.2% QoQ and 157.6% YoY. The earnings per share (EPS) for Q1FY26 is -₹1.50, compared to ₹0.70 in Q4FY25 and ₹2.70 in Q1FY25, illustrating a decrease of 314.3% QoQ and 155.6% YoY.

Operating Metrics

The total expenses for Q1FY26 amounted to ₹112.68 crores, showing a notable increase of 20.2% from the previous quarter's expenses of ₹93.74 crores. Compared to the previous year (Q1FY25), where expenses were reported at ₹98.59 crores, there is a year-over-year increase of 14.3%. This rise in expenses contributes to the overall financial performance and is a key factor in the net loss reported for the quarter. The tax for Q1FY26 is ₹0.16 crores, reflecting a significant decline of 92.4% QoQ from ₹2.11 crores in Q4FY25 and a 97.6% YoY decrease from ₹6.66 crores in Q1FY25. These figures highlight shifts in the company's operating costs and tax obligations during the period under review.